Inventor · disambiguated record
James Robert Blinn
Also filed as: BLINN JAMES · BLINN JAMES R · BLINN JAMES ROBERT
22 granted patents·18 pending applications·107 citations·filing 1984–2023
93Inventor score
Files withACLARIS THERAPEUTICS INC14INNOV17 LLC9PFIZER6CONFLUENCE LIFE SCIENCES INC5GAWECO ANDERSON2
Top patents by PatentIndex Score
40 records- 0196US10981906B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Apr 20, 2021·9 cites·21 claims
- 0294US11739086B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·4 cites·5 claims
- 0394US10800775B2Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Oct 13, 2020·8 cites·20 claims
- 0494US9695200B2Heterocyclic ITK inhibitors for treating inflammation and cancerCONFLUENCE LIFE SCIENCES INC·Filed 2016·Granted Jul 4, 2017·19 cites·7 claims
- 0592US11820775B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2021·Granted Nov 21, 2023·2 cites·34 claims
- 0690US12281111B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2023·Granted Apr 22, 2025·1 cites·7 claims
- 0785US12297203B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2023·Granted May 13, 2025·0 cites·5 claims
- 0882US11021482B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2019·Granted Jun 1, 2021·2 cites·21 claims
- 0982US9145393B2Arylpyridinone ITK inhibitors for treating inflammation and cancerCONFLUENCE LIFE SCIENCES INC·Filed 2015·Granted Sep 29, 2015·2 cites·17 claims
- 1081US9505765B24-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatmentCONFLUENCE LIFE SCIENCES INC·Filed 2013·Granted Nov 29, 2016·3 cites·24 claims
- 1181US9499551B2Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseasesCONFLUENCE LIFE SCIENCES INC·Filed 2015·Granted Nov 22, 2016·4 cites·10 claims
- 1277US6685617B1Inhibitors of α4β1 mediated cell adhesionUPJOHN CO·Filed 1999·Granted Feb 3, 2004·24 cites·9 claims
- 1369US9321750B2ROR modulators and their usesINNOV17 LLC·Filed 2013·Granted Apr 26, 2016·1 cites·7 claims
- 1469US4793180ADelayed action irreversible humidity indicatorAGM CARGO TIES INC·Filed 1984·Granted Dec 27, 1988·28 cites·12 claims
- 1567US2020039960A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2019·Application pending·0 cites
- 1666US2022372034A1Substituted pyrrolopyridines as jak inhibitorsACLARIS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1765US2019144429A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2019·Application pending·0 cites
- 1863US2016046597A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2014·Application pending·0 cites
- 1963US2018282304A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2018·Application pending·0 cites
- 2062US2018086736A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2017·Application pending·0 cites
- 2160US2017233371A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2017·Application pending·0 cites
- 2259US2019352300A1Pyrrolopyrimidine itk inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2358US10316038B2Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·0 cites·27 claims
- 2458US9708268B2ROR modulators and their usesGAWECO ANDERSON·Filed 2013·Granted Jul 18, 2017·0 cites·16 claims
- 2558US2024002380A1Rev-erb agonistsUNIV SAINT LOUIS·Filed 2023·Application pending·0 cites
- 2657US11420966B2Substituted pyrrolopyridines as JAK inhibitorsACLARIS THERAPEUTICS INC·Filed 2020·Granted Aug 23, 2022·0 cites·17 claims
- 2757US2022251191A1Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteinsARCH ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 2857US2019106439A1Heterocyclic itk inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2954US10150783B2Heterocyclic ITK inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2017·Granted Dec 11, 2018·0 cites·21 claims
- 3051US2022235043A1Substituted sulfonamide pyrrolopyridines as jak inhibitorsACLARIS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3147US2016130231A1Ror modulators and their usesINNOV17 LLC·Filed 2016·Application pending·0 cites
- 3241US9447069B2ROR modulators and their usesGAWECO ANDERSON·Filed 2013·Granted Sep 20, 2016·0 cites·16 claims
- 3341US2015328227A1Arylpyridinone itk inhibitors for treating inflammation and cancerCONFLUENCE LIFE SCIENCES INC·Filed 2015·Application pending·0 cites
- 3440US9701663B2Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereofINNOV17 LLC·Filed 2015·Granted Jul 11, 2017·0 cites·35 claims
- 3539US2017217956A1Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereofINNOV17 LLC·Filed 2015·Application pending·0 cites
- 3639US2016024086A1Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereofINNOV17 LLC·Filed 2015·Application pending·0 cites
- 3733US9884847B2Indazole retinoic acid receptor-related orphan receptor modulators and uses thereofINNOV17 LLC·Filed 2015·Granted Feb 6, 2018·0 cites·40 claims
- 3833US9771374B2Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereofINNOV17 LLC·Filed 2015·Granted Sep 26, 2017·0 cites·25 claims
- 3931US2015252022A1Retinoic acid receptor-related orphan receptor modulators and uses thereofINNOV17 LLC·Filed 2015·Application pending·0 cites
- 4031US2015252051A1Retinoic acid receptor-related orphan receptor modulators and uses thereofINNOV17 LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James Robert Blinn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →